CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
15.46 CAD
+0.32 (+2.11%)
CPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes CPH very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
CPH had a positive operating cash flow in the past year.
In the past 5 years CPH has always been profitable.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.77%, CPH belongs to the top of the industry, outperforming 91.43% of the companies in the same industry.
The Return On Equity of CPH (15.23%) is better than 88.57% of its industry peers.
The Return On Invested Capital of CPH (7.23%) is better than 88.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.45%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
CPH's Profit Margin has improved in the last couple of years.
CPH's Operating Margin of 25.51% is amongst the best of the industry. CPH outperforms 85.71% of its industry peers.
CPH's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 74.32%, CPH belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
Compared to 1 year ago, CPH has more shares outstanding
The number of shares outstanding for CPH has been reduced compared to 5 years ago.
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.56 indicates that CPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.56, CPH belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
CPH has a better Debt to FCF ratio (0.45) than 94.29% of its industry peers.
CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.12, CPH is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.56 |
ROIC/WACC0.87
WACC8.32%
2.3 Liquidity
A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
CPH has a worse Current ratio (1.30) than 62.86% of its industry peers.
CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CPH (0.98) is comparable to the rest of the industry.
The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 89.17%.
The Revenue has been growing by 8.25% on average over the past years. This is quite good.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.80, the valuation of CPH can be described as correct.
CPH's Price/Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 80.00% of the companies in the same industry.
CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
The Price/Forward Earnings ratio is 17.93, which indicates a rather expensive current valuation of CPH.
71.43% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
CPH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.8 | ||
| Fwd PE | 17.93 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 77.14% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.44 | ||
| EV/EBITDA | 14.59 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.33
PEG (5Y)1.3
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (1/9/2026, 7:00:00 PM)
15.46
+0.32 (+2.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap392.22M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target18.39 (18.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)2.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.8 | ||
| Fwd PE | 17.93 | ||
| P/S | 5.64 | ||
| P/FCF | 9.44 | ||
| P/OCF | 9.42 | ||
| P/B | 2.48 | ||
| P/tB | 12.37 | ||
| EV/EBITDA | 14.59 |
EPS(TTM)0.92
EY5.95%
EPS(NY)0.86
Fwd EY5.58%
FCF(TTM)1.64
FCFY10.59%
OCF(TTM)1.64
OCFY10.62%
SpS2.74
BVpS6.24
TBVpS1.25
PEG (NY)0.33
PEG (5Y)1.3
Graham Number11.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.56 |
F-Score7
WACC8.32%
ROIC/WACC0.87
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year137.29%
EBIT Next 3Y50.19%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.8 and the Price/Book (PB) ratio is 2.48.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.